You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: NIADESCRIPTION (provided by applicant): A strong unmet need exists to develop new treatments for anemias associated with chronic disease states, collectively referred to as anemia of chronic inflammation (ACI). ACI is highly prevalent in the U.S. and makes alarge contribution to public morbidity and mortality. Despite billions of dollars spent annually to treat ACI patients, current therapies lack e ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Novel Biomarkers for Early Detection of Aspergillosis
SBC: SOUTHEAST TECHINVENTURES INC Topic: NIAIDDESCRIPTION (provided by applicant): Invasive aspergillosis (IA) caused by the fungus Aspergillus fumigatus is the most frequent fungal cause of death in immunocompromised patients. The number of patients at risk for developing IA is steadily increasing due to advances in medicine. Early and accurate diagnosis of IA is critical to patient outcome, yet is exceedingly difficult due to the lack of sp ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
CMV Therapeutic Vaccine for the Treatment of Glioblastoma
SBC: Annias Immunotherapeutics, Inc. Topic: NCIDESCRIPTION (provided by applicant): Recently, temozolomide (TMZ), a myelosuppressive alkylating chemotherapy, has shown a benefit in patients with glioblastoma multiformes (GBM), but median survival is still less than 15 months. Moreover, these conventional chemotherapies lack specificity and result in incapacitating damage to surrounding normal brain and systemic tissues. Immunotherapy may provi ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
A Quantitative Optical Sensor to Monitor Pre-Clinical Tumor Vascular Physiology
SBC: Zenalux Biomedical, Inc. Topic: NCIDESCRIPTION (provided by applicant): Angiogenesis and hypoxia can significantly influence the efficacy of therapy and the behavior of surviving tumor cells. This important fact is supported by a vast amount of literature on pre-clinical models and clinical studies. There is growing demand for technologies to measure tumor hypoxia and angiogenesis temporally and spatially in vivo to enable advance ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Novel SET Antagonists for the Treatment of Chronic Myelogenous Leukemia
SBC: ONCOTIDE PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION (provided by applicant): Chronic Myelogenous Leukemia (CML) affects nearly 14,000 patients worldwide and is a disorder of the pluripotent hematopoietic stem cells with two distinct phases. The protracted myelopoliferative chronic phase is followed by a rapidly fatal blast crisis. In CML, a chromosomal translocation leads to production of the Philadelphia Chromosome (Ph1) in which the ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Class for Opioid Drugs
SBC: ALGYNOMICS, INC. Topic: NIDADESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Significant CT Radiation Dose Reduction with Equally Sloped Tomography
SBC: TOMOSOFT TECHNOLOGIES, LLC Topic: NIBIBDESCRIPTION (provided by applicant): CT has become a routine medical tool in diagnosis of diseases and visualization of critical interventional procedures. The number of CT examinations has significantly increased over the past two decades in the US, and reached approximately 72 million in 2007 alone [5,8]. According to the 2009 report from the National Council on Radiation Protection and Measurem ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel method for inhibiting diabetic retinopathy
SBC: VASCULAR PHARMACEUTICALS Topic: NEIDESCRIPTION (provided by applicant): The long-term objective of the proposed study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy. Insulin-like growth factor-I (IGF-I) has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease. However directly inhibiting the IGF-I receptor may be lead to neurotoxicity. Following ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
External Glaucoma Drainage Device
SBC: CAMRAS VISION, INC. Topic: NEIDESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of blindness in the world affecting 67 million people. Reduction of intraocular pressure (IOP) is the only proven treatment for delaying the progression of vision loss caused by glaucoma. The current surgical options for IOP lowering are unpredictable and suboptimal in terms of success rate. One of the primary reasons for s ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Using combinatorial control to improve transgene expression specificity in plants
SBC: GRASSROOTS BIOTECHNOLOGY, INC. Topic: NIGMSDESCRIPTION (provided by applicant): It is currently estimated that 15% of the world's population is undernourished and 5 million childhood deaths a year are attributable to malnutrition. The ability to feed the world in the future will be even more difficult due to population growth, climate change, water scarcity, and competition for land. It is widely recognized that advances in agricultu ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health